Arficus

AI based screening and diagnostic platform

CURRENT IMPACT

As on August 2023

95

primary healthcare facilities enabled with MEDHINI

84,000+

patients screened using MEDHINI

Samridh support

With SAMRIDH’s support, Arficus is targeting 150 healthcare facilities (both public and private) for the deployment of its solution, MEDHINI. Arficus is provided with returnable grant support to meet the state-wise distribution is anticipated to be: 35 in Chhattisgarh, 35 in Rajasthan, 40 in Odisha, 20 in Sikkim, 20 in Arunachal Pradesh. The population covered is 30 lakhs.

Geographical Focus
  • Sikkim, Arunachal Pradesh, Chhattisgarh, Rajasthan and Odisha 
Potential Impact

  • 1Lac+

    population directly benefited

African Presence

Arficus has deployed MEDHINI in 6 centres of East and West Africa with all necessary regulatory approvals for deployment in European and African countries. MEDHINI also has UK-NIHR regulatory approval enabling it for mass deployment over the entire continent of Africa. It takes into account parameters and constraints for each area of deployment and caters the software for easy operation without the need for highly specialised training. So far MEDHINI has undertaken over 375000 diagnostic tests in vulnerable populations.

TB

Respiratory illnesses caused by TB, asthma, COPD, pneumonia, and lung cancer are the leading causes of morbidity and mortality Globally

32
%

of the global burden of respiratory diseases lies with India

20.5
%

Up to 20.5% of the post-acute COVID-19 deaths were attributed to respiratory ailments. In addition to this, nearly 3.6 crore Indians showed symptoms of long term respiratory trouble even after recovery from COVID-19. 

Respiratory illnesses have become rampant in developing and underdeveloped countries like India, especially post COVID-19. One of the main problems due to which respiratory diseases persist is due to the lack of cost-effective and lab-free methods for early screening and diagnosis. Screening and management of respiratory diseases is difficult in remote locations, especially in the north-eastern belt and other underdeveloped states across the country due to a lack of experienced doctors as well as specialised infrastructure. Hence, there is an urgent need for screening and diagnostic solutions that can be rapidly deployed at scale to screen and monitor millions of people suffering from respiratory diseases. Such a tool needs to be easy to use, require minimal training and be extremely cost-effective, so that it is available for the people at the bottom of the pyramid.

MEDHINI- AI based disease screening and diagnostic platform

Arficus has launched MEDHINI which is a combination of a Portable X ray machine  and Artificial Intelligence Disease Screening/Diagnostics/Prediction SaaS-SAMD platform.   This solution is highly adaptable and innovative, using AI, Arficus aims to provide healthcare infrastructure where screening and diagnosis of respiratory illnesses can be conducted without too much dependency on the high-end equipment & specialists in an extremely cost-effective manner which will lead to better management and prognosis of the patients.

The solution is capable of screening pulmonary diseases like COVID-19, Tuberculosis, Pneumonia and Lung Cancer by analysing X-Ray scans, CT scans or voice notes of a patient to provide diagnosis within minutes.